Lyell Immunopharma, Inc.
LYEL
$10.76
-$0.21-1.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 60.00K | 65.00K | 61.00K | 63.00K | 54.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.00K | 65.00K | 61.00K | 63.00K | 54.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 60.00K | 65.00K | 61.00K | 63.00K | 54.00K |
| SG&A Expenses | 50.12M | 52.59M | 52.04M | 50.69M | 54.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.92M | -4.55M | -4.25M | -3.89M | -3.45M |
| Total Operating Expenses | 211.68M | 219.92M | 219.40M | 216.73M | 225.25M |
| Operating Income | -211.62M | -219.85M | -219.34M | -216.66M | -225.20M |
| Income Before Tax | -331.40M | -334.52M | -342.99M | -203.99M | -210.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -331.40 | -334.52 | -342.99 | -203.99 | -210.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -331.40M | -334.52M | -342.99M | -203.99M | -210.26M |
| EBIT | -211.62M | -219.85M | -219.34M | -216.66M | -225.20M |
| EBITDA | -195.34M | -201.80M | -199.70M | -197.00M | -205.11M |
| EPS Basic | -23.61 | -24.32 | -25.55 | -16.03 | -16.59 |
| Normalized Basic EPS | -8.48 | -9.08 | -9.34 | -9.43 | -9.79 |
| EPS Diluted | -23.61 | -24.32 | -25.55 | -16.03 | -16.59 |
| Normalized Diluted EPS | -8.48 | -9.08 | -9.34 | -9.43 | -9.79 |
| Average Basic Shares Outstanding | 56.36M | 54.34M | 52.30M | 50.94M | 50.69M |
| Average Diluted Shares Outstanding | 56.36M | 54.34M | 52.30M | 50.94M | 50.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |